Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort

Cancer

Volumn 115, Issue 11, 2009, Pages 2400-2409

  Giltnane, Jennifer M ^a   Moeder, Christopher B ^a   Camp, Robert L ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Automated quantitative analysis; Epidermal growth factor receptor; HER 2; HER 3; HER 4; Immunohistochemistry; Survival

Indexed keywords

CANNERTINIB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERBB PROTEIN; ESTROGEN RECEPTOR; PERTUZUMAB; PROGESTERONE RECEPTOR; RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; DISEASE MARKER; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 66649127267     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24277     Document Type: Article

References (26)

1. Schlessinger J.Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211-225.
2. Osborne CK, Shou J, Massarweh S, Schiff R.Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005;11:865s-870s. (Pubitemid 40111098)
3. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer. 2004;91:1532-1542. (Pubitemid 39486359)
4. Esteva FJ, Hortobagyi GN, Sahin AA, et al. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res. 2001;7:171-177. (Pubitemid 33716851)
5. Hudelist G, Singer CF, Manavi M, Pischinger K, Kubista E, Czerwenka K.Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat. 2003;80:353-361. (Pubitemid 37046760)
6. Kew TY, Bell JA, Pinder SE, et al. c-erbB-4 protein expression in human breast cancer. Br J Cancer. 2000;82:1163-1170. (Pubitemid 30128873)
7. Suo Z, Risberg B, Kalsson MG, et al. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol. 2002;196:17-25. (Pubitemid 34071574)
8. Suo Z, Yang H, Mei Q, Skovlund E, Cui J, Nesland JM.Type 1 protein tyrosine kinases in Chinese breast carcinomas: a clinicopathologic study. Int J Surg Pathol. 2001;9:177-187. (Pubitemid 32979969)
9. Tischkowitz M, Brunet JS, Begin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134. (Pubitemid 47272190)
10. Travis A, Pinder SE, Robertson JF, et al. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer. 1996;74:229-233. (Pubitemid 126732896)
11. Wiseman SM, Makretsov N, Nielsen TO, et al. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer. 2005;103:1770-1777.
12. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM.Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003;200:290-297. (Pubitemid 36827302)
13. Camp RL, Chung GG, Rimm DL.Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8:1323-1327. (Pubitemid 35373567)
14. Camp RL, Dolled-Filhart M, King BL, Rimm DL.Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res. 2003;63:1445-1448. (Pubitemid 36373626)
15. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL.Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst. 2005;97:1808-1815. (Pubitemid 43033901)
16. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL.Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 2006;66: 5487-5494. (Pubitemid 43844977)
17. Singletary SE, Connolly JL.Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin. 2006;56:37-47; quiz 50-51 (Pubitemid 43228386)
18. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847. (Pubitemid 28331029)
19. Berger AJ, Camp RL, DiVito KA, Kluger HM, Halaban R, Rimm DL.Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res. 2004; 64:8767-8772. (Pubitemid 39552095)
20. Rubin MA, Zerkowski MP, Camp RL, et al. Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol. 2004; 164:831-840. (Pubitemid 38235465)
21. Boyd JC, Lacher DA.A multi-stage Gaussian transformation algorithm for clinical laboratory data. Clin Chem. 1982;28:1735-1741. (Pubitemid 12039721)
22. Linggi B, Carpenter G.ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 2006;16:649-656. (Pubitemid 44809890)
23. Pick E, Kluger Y, Giltnane JM, et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 2007;67:2932-2937. (Pubitemid 46724827)
24. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
25. Siziopikou KP, Ariga R, Proussaloglou KE, Gattuso P, Cobleigh M.The challenging estrogen receptor-negative/progesterone receptor-negative/HER-2- negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J. 2006;12:360-362.
26. Hobday TJ, Perez EA.Molecularly targeted therapies for breast cancer. Cancer Control. 2005;12:73-81. (Pubitemid 40647050)